Heron Therapeutics Announces Partnership with CrossLink Life Sciences to Expand Promotional Effort for ZYNRELEF®, the First and Only Non-Opioid Dual Acting Local Anesthetic for Post-Operative Pain

SAN DIEGO, Jan. 7, 2024 /PRNewswire/ -- Heron Therapeutics, Inc. , a commercial-stage biotechnology company, today announced that it has entered into a five-year distributor partnership with...

Related Keywords

United States ,Ira Duarte ,Thomas Fleetwood ,Drug Administration ,Nasdaq ,European Union ,Prnewswire Heron Therapeutics Inc ,Heron Therapeutics Inc ,Crosslink Life Sciences ,Exchange Commission ,Craig Collard ,Chief Executive Officer ,European Commission ,United Kingdom Regulatory Authority ,Heron Therapeutics ,Private Securities Litigation Reform Act ,Boxed Warning ,Media Contact ,Vice President ,Chief Financial ,Markets ,